AVITA MEDICAL LTD SPON ADS EACH REP 20 ORD SHS RCEL 深 滬
等待開盤 12-17 09:30:00 美东时间
3.33
-0.070
-2.06%
華盛通- 最 高3.42
- 今 開3.40
- 成交量 28.03万股
- 最 低 3.25
- 昨 收 3.40
- 總市值 8997.29万
- 52周最高 14.16
- 市盈率 靜 --
- 換手率 1.04%
- 52周最低 3.25
- 委 比 89.37%
- 總股本 2701.89万
- 歷史最高 49.11
- 量 比 1.66
- 振 幅 5.00%
- 歷史最低 3.25
- 每 手 1
- 風險率 2.56%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BTIG Upgrades AVITA Medical to Neutral
BTIG analyst Ryan Zimmerman upgrades AVITA Medical (NASDAQ:RCEL) from Sell to Neutral.
11-20 20:14
电话会总结 ｜ AVITA Medical(RCEL)2025财年Q3业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据AVITA Medical业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** 2025年第三季度营收为1,710万美元，同比下降13%（2024年第三季度为1,950万美元）。全年营收指引下调至7,000-7,400万美元，低于此前指引的7,600-8,100万美元。 **盈利能力：** 毛利率为81.3%，同比下降2.4个百分点（2024年第三季度为83.7%）。ReCell产品线毛利率维持在83.6%的强劲水平。 **亏损情况：** 净亏损为1,320万美元（每股亏损0.46美元），同比改善19%（2024年第三季
11-07 12:02
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12
AVITA Medical Welcomes Support for RECELL® in Burns in Australia
澳大利亚医疗用品咨询委员会（MSAC）已推荐将RECELL®纳入医保福利计划，用于治疗成人及儿童的严重急性烧伤。MSAC认可RECELL安全有效，能促进伤口愈合、减少供体部位损伤，并缩短住院时间。RECELL使用患者自身皮肤细胞喷洒治疗，无需大面积移植，减轻疼痛和疤痕。此次推荐适用于成人烧伤面积≥20%、儿童≥10%及面部烧伤患者。
10-28 20:30
美股大行评级 | 潜在最高涨幅37.45%，甲骨文获多家机构上调目标价；瑞穗上调美光科技目标价升至240美元
今日重点评级关注：韦德布什：维持Artiva Biotherapeutics"跑赢大市"评级，目标价从18美元升至23美元；巴克莱：维持Cellectis"超配"评级，目标价从4美元升至8美元
10-20 10:03
AVITA Medical任命临时首席执行官
专注于皮肤修复设备及自体细胞疗法的开发和商业化企业AVITA Medical（RCEL）股价暴跌27.2%。该公司在董事会决定后，已任命Cary Vanc...
10-17 23:42
Reported Earlier, AVITA Medical Announces Leadership Transition With Cary Vance As Interim CEO And Preliminary Q3 Revenue Of $17M
Board Chairman Cary Vance appointed Interim CEOBoard member Jan Stern Reed appointed Lead Independent DirectorThird quarter 2025 preliminary revenue expected to be approximately $17 million
10-17 14:02
AVITA Medical Announces CEO Transition
AVITA Medical announces Cary Vance as Interim CEO and Jan Stern Reed as Lead Independent Director following Jim Corbett's departure. The company expects Q3 2025 revenue of ~$17 million and is seeking a permanent CEO, with Vance considered as a candidate.
10-16 22:15
AVITA Medical's RECELL Eligible For Up To $4,875 In CMS Reimbursement For Acute Trauma And Surgical Wounds
Hospitals may receive up to $4,875 in added reimbursement when using RECELL to treat non-burn full-thickness acute wounds resulting from trauma or surgeryEffective October 1, the add-on payment eases financial barriers,
10-01 20:35
CMS New Technology Add-On Payment Expands Access to RECELL® for Patients with Non-Burn Acute Wounds
As of October 1, 2025, U.S. hospitals using the RECELL System to treat acute, non-burn trauma and surgical full-thickness wounds are eligible for additional reimbursement of up to $4,875 per case under the Centers for Medicare & Medicaid Services (CMS) New Technology Add-on Payment program. The policy, effective through September 30, 2026, aims to reduce financial barriers and encourage broader use of the innovative skin cell therapy, which requi...
10-01 12:30
